Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII

Radiotherapy and Oncology

Volumn 83, Issue 3, 2007, Pages 326-332

  Aerts, Hugo J W L ^a   Dubois, Ludwig ^a,b   Hackeng, Tilman M ^c   Straathof, Roel ^a   Chiu, Roland K ^a   Lieuwes, Natasja G ^a   Jutten, Barry ^a   Weppler, Sherry A ^a   Lammering, Guido ^a   Wouters, Bradly G ^a   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cetuximab; EGFR; EGFRvIII; Imaging probe evaluation

Indexed keywords

ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MECHANICAL PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARBOXYLIC ACIDS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FLUORESCENT DYES; HUMANS; MICE; MICE, NUDE; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34250220039     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.04.030     Document Type: Article

References (29)

1. Akimoto T., Hunter N.R., Buchmiller L., Mason K., Ang K.K., and Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5 (1999) 2884-2890
2. Baselga J., and Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23 (2005) 2445-2459
3. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
4. Cai W., Chen K., He L., Cao Q., Koong A., and Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using (64)Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging (2007)
5. Dirksen A., Meijer E.W., Adriaens W., and Hackeng T.M. Strategy for the synthesis of multivalent peptide-based nonsymmetric dendrimers by native chemical ligation. Chemical communications (Cambridge, England) (2006) 1667-1669
6. Dittmann K., Mayer C., and Rodemann H.P. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76 (2005) 157-161
7. Eicheler W., Krause M., Hessel F., Zips D., and Baumann M. Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. Radiother Oncol 76 (2005) 151-156
8. Eriksen J.G., Steiniche T., and Overgaard J. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol 74 (2005) 93-100
9. Frieze D.A., and McCune J.S. Current status of cetuximab for the treatment of patients with solid tumors. Ann pharmacother 40 (2006) 241-250
10. Hebbar M., Wacrenier A., Desauw C., et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17 (2006) 855-857
11. Herbst R.S. Review of epidermal growth factor receptor biology. Int j Radiat Oncol Biol Phys 59 (2004) 21-26
12. Herbst R.S., and Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94 (2002) 1593-1611
13. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
14. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 (2000) 2166-2174
15. Imai K., and Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev 6 (2006) 714-727
16. Krause M., Ostermann G., Petersen C., et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 76 (2005) 162-167
17. Lammering G. Molecular predictor and promising target: will EGFR now become a star in radiotherapy?. Radiother Oncol 74 (2005) 89-91
18. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., and Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer cell 7 (2005) 301-311
19. Mamot C., Drummond D.C., Greiser U., et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 63 (2003) 3154-3161
20. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20 (2002) 1S-13S
21. Milas L., Fan Z., Andratschke N.H., and Ang K.K. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 58 (2004) 966-971
22. Moscatello D.K., Holgado-Madruga M., Godwin A.K., et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55 (1995) 5536-5539
23. Pedersen M.W., Meltorn M., Damstrup L., and Poulsen H.S. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 12 (2001) 745-760
24. Perk L.R., Visser G.W., Vosjan M.J., et al. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 46 (2005) 1898-1906
25. 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 45 (2004) 1683-1687
26. 99mTc-ethylenedicysteine-C225 monoclonal antibody. Anticancer Drugs 14 (2003) 49-56
27. Sok J.C., Coppelli F.M., Thomas S.M., et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12 (2006) 5064-5073
28. 89Zr-labeled monoclonal antibodies. J Nucl Med 44 (2003) 1271-1281
29. Xiong H.Q., Rosenberg A., LoBuglio A., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 22 (2004) 2610-2616